Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Volume Increase – Time to Buy?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw unusually-high trading volume on Thursday . Approximately 2,928,793 shares were traded during trading, an increase of 114% from the previous session’s volume of 1,366,514 shares.The stock last traded at $10.2820 and had previously closed at $9.94.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BAYRY shares. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Finally, Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The stock has a 50 day moving average of $11.18 and a 200 day moving average of $11.27. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $40.33 billion, a price-to-earnings ratio of -16.04, a price-to-earnings-growth ratio of 3.17 and a beta of 0.59.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.